Company intelligence / Profile preview

Seaport Global

Boston, Massachusetts, United Statesseaporttx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Seaport Therapeutics is advancing oral prodrugs via the Glyph platform for neuropsychiatric disorders. Lead candidate SPT-300 (GlyphAllo, allopregnanolone prodrug) is entering Phase 2b for major depressive disorder; SPT-320 (GlyphAgo, agomelatine prodrug) entering Phase 1 for generalized anxiety disorder; SPT-348 (Glyph 2BLSD) in preclinical for mood/neuropsychiatric disorders.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Seaport Global.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seaport Global.

Explore the full profile